Novel radiation mitigators and anticancer drugs Yel002

RadMit Inc. focuses on the development of novel small molecule drugs to treat genomic instabilities and to mitigate diseases caused by accidental radiation exposure by boosting cellular DNA repair and anti-inflammation capabilities. The Company will primarily focus on development of treatments for genetic instability diseases such as Ataxia Telangiectasia (Lois-Barr Syndrome) as well as Xeroderma pigmentosa, Bloom’s Syndrome, Nijmegen Breakage Syndrome, Fanconia Anemia and Li Fraumeni Syndrome. In addition, the Company focuses on the development of a small molecule drug for the treatment of genomic instabilities caused by accidental exposure to radiation. There is strong commercial interest from pharmaceutical companies in new drugs for orphan and other diseases.
 

RadMit Inc. (RadMit) has been founded by Prof. Robert H. Schiestl and the Management Team and incorporated in Los Angeles. The company primarily raises money investments for mitigation of damages caused by radiation exposure and other toxic exposures and other diseases.
 

The Company’s scientific founder has invented a proprietary screening assay against radiation induced genetic instability and toxicity at the University of California Los Angeles (UCLA). Using this proprietary assay, Prof. Dr. Robert H. Schiestl, the owner, inventor, president, CEO, and CSO of the company and his team screened more than 16,000 small molecule compounds for efficacy to boost DNA repair proteins after radiation exposure supported by $31 million by the NIH. This substantial screening process resulted in the identification of several hits, the most promising being Yel002. From mice irradiated with an LD100 which all die from the radiation, we could rescue 100% after injecting the first dose of our radiation mitigator 24 hours after radiation. Radiation induced leukemia was reduced from 90% down to 40%. And spontaneous leukemia from 20% down to 0%. Atm deficient mice of which 90% die from lymphoma lived 16 weeks longer after weekly injection with our radiation mitigator. This is equivalent to 20 years in human life expectancy. This would be a major advance in the management of the diseases and longevity. In vitro proteomics experiments showed that our radiation mitigator induced DNA repair which is our own bodily defence against external and internal toxic substances. In particular, it induced Atm signalling, nonhomologous end joining, base excision repair, DNA damage binding protein and structural maintenance of chromosome proteins and antiinflammatory functions and neuroprotective functions. It also protected cells against UV light, chemical carcinogens, chemical warfare agents, radioactive iodine, and cigarette smoke extract. Thus, uses include a novel biological sunscreen undoing the damage to the skin rather than shielding, and for smokers reducing lung cancer risk after smoking a cigarette do undue the smoking damage and tons of others. It also prolonged the life of normal human karatinocytes 15% undergoing senescence which is ageing. Thus, our drugs could result in longer cancer free life making everyone a potential customer. YEL002 worked in yeast, human cells, zebrafish and mice and new data show it also treats a host of additional diseases in human patients for which we are doing new clinical trials.
 

Based on these results, the Company believes that its lead substance is exceptionally well suited for the treatment of a host of different diseases with the aim to reduce the cancer risk in such patients and for the mitigation of damages caused by radiation and other toxic exposure. It is a completely novel paradigm to use a chemical overexpressing DNA repair proteins and anti-inflammatory functions for radiation mitigation, in cancer chemoprevention and life extension.

The Company is working on a worldwide exclusive license to 1 patent application filed by the University of Los Angeles claiming the lead substances for the mitigation and treatment of symptoms of genomic instability disorders and as radiation mitigators. In addition, the Company is in the process of filing several further patent applications covering additional diseases to achieve maximum IP protection for its product. With the many uses this drug could develop into a blockbuster drug.

Robert H. Schiestl, RadMit Inc., please contact me at drrobert.schiestl@protonmail.com